VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 510 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2014. The put-call ratio across all filers is 1.37 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $103,000 | -99.9% | 7,688 | -25.4% | 0.03% | -34.1% |
| Q2 2017 | $178,000,000 | +97.8% | 10,303 | +6.2% | 0.04% | +76.0% |
| Q1 2017 | $90,000,000 | +55.2% | 9,703 | +143.1% | 0.02% | +150.0% |
| Q4 2016 | $58,000,000 | +62265.6% | 3,992 | +5.7% | 0.01% | -41.2% |
| Q3 2016 | $93,000 | +1062.5% | 3,775 | +792.4% | 0.02% | +466.7% |
| Q2 2016 | $8,000 | -11.1% | 423 | +21.6% | 0.00% | 0.0% |
| Q1 2016 | $9,000 | -89.5% | 348 | -59.0% | 0.00% | -90.6% |
| Q4 2015 | $86,000 | +132.4% | 848 | +305.7% | 0.03% | +146.2% |
| Q3 2015 | $37,000 | -72.6% | 209 | -65.7% | 0.01% | -72.3% |
| Q2 2015 | $135,000 | +11.6% | 610 | -0.7% | 0.05% | +20.5% |
| Q1 2015 | $121,000 | +61.3% | 614 | +17.4% | 0.04% | +56.0% |
| Q4 2014 | $75,000 | -6.2% | 523 | -14.1% | 0.02% | +56.2% |
| Q3 2014 | $80,000 | +73.9% | 609 | +42.0% | 0.02% | -33.3% |
| Q2 2014 | $46,000 | – | 429 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |